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Abstract 1 
We examined hemoglobin (Hb, g/L), iron status (zinc protoporphyrin, ZPP, ȝmol/mol heme, and 2 
transferrin receptor, TfR, mg/L), and inflammation (C-reactive protein, CRP and alpha-1 3 
glycoprotein, AGP) in pregnant Ghanaian women who participated in a randomized controlled 4 
trial. Women (n=1320) received either 60 mg Fe + 400 µg folic acid (IFA);  18 micronutrients 5 
including 20 mg Fe (MMN); or small-quantity lipid-based nutrient supplements (SQ-LNS, 118 6 
kcal/d) with the same micronutrient levels as in MMN, plus 4 additional minerals (LNS) daily 7 
during pregnancy. Intention-to-treat analysis included 349, 354, and 354 women in the IFA, 8 
MMN and LNS groups, respectively, with overall baseline mean Hb and anemia (Hb <100) 9 
prevalence of 112 and 13.3%, respectively. At 36 gestational weeks, overall Hb was 117 and 10 
anemia prevalence was 5.3%. Compared with the IFA group, the LNS and MMN groups had 11 
lower mean Hb (120±11 vs 115±12 and 117±12, respectively; p<0.001), higher mean ZPP 12 
(42±30 vs 50±29 and 49 ±30; p=0.010) and TfR (4.0±1.3 vs 4.9±1.8 and 4.6±1.7; p<0.001), and 13 
greater prevalence of anemia (2.2% vs 7.9% and 5.8%; p=0.019), elevated ZPP (>60) [9.4% vs 14 
18.6% and 19.2%; p=0.003] and elevated TfR (>6.0) [9.0% vs 19.2% and 15.1%; p=0.004]. CRP 15 
and AGP concentrations did not differ among groups. We conclude that among pregnant women 16 
in a semi-urban setting in Ghana,  supplementation with SQ-LNS or MMN containing 20 mg 17 
iron resulted in lower Hb and iron status but had no impact on inflammation, when compared 18 
with iron (60 mg) plus folic acid (400 µg). The amount of iron in such supplements that is most 19 
effective for improving both maternal Hb/iron status and birth outcomes requires further 20 
evaluation. This trial was registered at ClinicalTrials.gov as: NCT00970866. 21 
 22 
ANTENATAL LNS SUPPLEMENTATION IN GHANA Page 5 / 45 
  
Keywords   lipid-based nutrient supplements, LNS, prenatal supplementation, multiple 23 
micronutrients, hemoglobin, iron status, inflammation    24 
ANTENATAL LNS SUPPLEMENTATION IN GHANA Page 6 / 45 
  
Introduction 25 
 Poor nutrient intake during pregnancy has been associated with several adverse 26 
consequences.  It is estimated that up to 50% of the anemia among pregnant women in many 27 
developing country settings is due to iron deficiency (van den Broek et al., 1998) usually as a 28 
result of low dietary iron intake (World Health Organization, 1992)  and poor iron bioavailability 29 
due to over-reliance on plant-based diets high in inhibitors of iron absorption such as phytate 30 
(Tatala et al., 1998). Consequences of anemia include reduced work capacity and increased risk 31 
of mortality for the mother, and premature delivery, low birth weight and poor mental 32 
development for the infant (Ren et al., 2007, International Anemia Consultative Group (INACG), 33 
2002). While normal pregnancy is found to be associated with an increased inflammatory 34 
response (Picklesimer et al., 2008, Sacks et al., 1998), this response may be modified by macro- 35 
or micro-nutrients (Roberts et al., 2003). Higher intakes of folic acid (Bertran et al., 2005) and 36 
vitamin B6 (Friso et al., 2001) have been  associated with lower concentration of C-reactive 37 
protein (CRP), a common biomarker of inflammation. Several other dietary factors including 38 
essential fatty acids, EFAs (Rallidis et al., 2003) and antioxidants (Brighenti et al., 2005, Devaraj 39 
and Jialal, 2000) are also associated with the reduction of CRP concentration. Elevated CRP 40 
concentration in pregnancy is related to the development of pre-eclampsia and preterm delivery 41 
(Elovitz, 2006).  42 
A major recommendation for increasing nutrient intake among pregnant women in 43 
developing countries is the one developed by WHO (WHO), which is the consumption of 44 
iron/folic acid (IFA) supplements containing 30-60 mg iron and 400 µg folic acid. In meta-45 
analyses, this strategy, compared with no iron or placebo, reduced the risk of maternal anemia by 46 
69-70 % (Imdad and Bhutta, 2012, Pena-Rosas et al., 2012) and iron deficiency by 57% (Pena-47 
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Rosas et al., 2012), but appeared to increase the risk of reported side effects (relative risk (RR) = 48 
2.36; 95% CI: 0.96 -5.82) particularly at iron doses of 60 mg or higher (Pena-Rosas et al., 2012). 49 
The WHO/UNICEF/UNU UNIMMAP (United Nations International Multiple Micronutrient 50 
Preparation) formulation containing 15 vitamins and minerals was more recently developed 51 
(UNICEF/WHO/UNU) to combat other possible deficiencies, e.g. for vitamins A, C and B12, 52 
which may also contribute to anemia (World Health Organization, 1992). The dose of iron in the 53 
UNIMMAP was set at 30 mg (below 60 mg) for the following reasons: (a) the presence of 54 
vitamins A, B2 and C in the UNIMMAP would enhance the absorption and utilization of iron, 55 
and therefore the lower amount of iron should be sufficient, (b) a lower iron dose would be 56 
associated with less negative side effects and therefore better adherence, (c) including 60 mg of 57 
iron would mean including at least 30 mg of zinc (to avoid possible negative influence of iron on 58 
zinc absorption), bringing the total amount of metals to 90 mg, which is likely to increase 59 
negative side effects, and (d) UNIMMAP may be used in conjunction with additional iron /folic 60 
acid tablets in individual cases of more severe anemia (assuming it is caused by iron deficiency). 61 
Meta-analyses suggested that supplementation with UNIMMAP and similar products (mostly 62 
containing 11 or more micronutrients including 30 mg iron) had the same effect on maternal 63 
hemoglobin and iron status as iron (usually at 60 mg dose) with or without folic acid (Allen and 64 
Peerson, 2009, Haider et al., 2011), while also reducing the risk of low birth weight (Fall et al., 65 
2009, Haider and Bhutta, 2012, Ramakrishnan et al., 2012).  66 
Our group developed small quantity (20 g/d) lipid-based nutrient supplements (SQ-LNS) 67 
for  pregnant and lactating women (Arimond et al., 2013) to provide micronutrients together with 68 
EFAs, using a minimum food base that supplies a small amount of energy (118 kcal/d) and high 69 
quality protein (2.6 g/d). In many populations, total energy intake among pregnant and lactating 70 
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women may be adequate, but the EFA content of the usual diet may be low (Michaelsen et al., 71 
2011). The micronutrient composition of the SQ-LNS was generally based on the UNIMMAP 72 
formulation and a similar product used in Guinea Bissau (Kaestel et al., 2005), but we further 73 
reduced the daily iron dose to 20 mg, based on evidence that  20 mg day-1 may be an adequate 74 
dose to prevent iron deficiency anemia during pregnancy (even for women who are iron deficient 75 
at entry to prenatal care) and causes fewer gastrointestinal side effects, compared to higher doses 76 
of iron (Zhou et al., 2009). We estimated (Arimond et al., 2013) that in addition to iron coming 77 
from the usual diet, the 20 mg of iron from a daily supplement would meet the recommended 78 
dietary allowance (RDA) of 27 mg iron during pregnancy (and be close to the 30 mg/d dose in 79 
the UNIMMAP formulation) while not greatly exceeding the RDA (9 mg/d) for iron during 80 
lactation (IOM, 2001, Arimond et al., 2013). 81 
Currently, there is a growing interest in the potential use of Small-Quantity Lipid-based 82 
Nutrient Supplements (SQ-LNS) among pregnant women in developing-country settings 83 
(Hambidge et al., 2014, Research Engagement on Food Innovation for Nutritional Effectiveness 84 
(REFINE), 2013), because of evidence suggesting a positive impact of the product on certain 85 
pregnancy outcomes (Adu-Afarwuah et al., 2015). However, little is known about the impact of 86 
SQ-LNS on maternal outcomes such as anemia, iron status and inflammation. We previously 87 
reported (Adu-Afarwuah et al., 2015), that compared to IFA and a multiple micronutrient 88 
(MMN) capsule with most of the same micronutrients as the SQ-LNS, the SQ-LNS promoted 89 
fetal growth in vulnerable women, particularly primiparas, whilst the occurrence of serious 90 
adverse events did not differ between the 3 groups. In the current analysis, we compare the effect 91 
of the 3 supplementation regimens (IFA, MMN and SQ-LNS), on maternal hemoglobin (Hb), 92 
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iron status, and two biomarkers of inflammation (CRP and alpha-1 glycoprotein, AGP) during 93 
pregnancy.   94 
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Methods 95 
Study setting, design, participants and blinding 96 
The iLiNS DYAD study in Ghana was conducted in several adjoining semi-urban 97 
communities in the Yilo Krobo and the Lower Manya Krobo Districts about 70 km north of 98 
Accra, Ghana. Details of the study setting, participants, design, randomization and masking 99 
schemes, and other key procedures have been reported elsewhere (Adu-Afarwuah et al., 2015). 100 
In brief, the study was designed as a partially double-blind, parallel, individually randomized, 101 
controlled trial with three equal-size groups. Pregnant women attending usual ante-natal clinics 102 
in four main health facilities in the area between December 2009 and December 2011 completed 103 
a screening questionnaire if they were  18 years old, 20 weeks gestation (as determined by the 104 
antenatal clinics mostly by fundal height), and had an antenatal card complete with history and 105 
examination. Informed consent for the screening was obtained by trained study workers at the 106 
antenatal clinics. Following screening, women were excluded if the antenatal card indicated HIV 107 
infection, asthma, epilepsy, tuberculosis or any malignancy. Additional exclusion criteria were 108 
known milk or peanut allergy, not residing in the area, intention to move within the next two 109 
years, unwillingness to receive field workers or take study supplement, participation in another 110 
trial, or gestational age (GA) >20 weeks before completion of the enrolment process.  111 
Women who passed the screening were visited in their homes, where details of the study 112 
were provided, and those willing to participate were recruited, after signing or thumb-printing 113 
informed consent. Recruited women remaining eligible underwent a baseline laboratory 114 
assessment after consent, and were immediately randomized to receive one of three treatments 115 
daily: (a) 60 mg iron plus 400 µg folic acid (hereafter, IFA supplement or group); (b) multiple 116 
micronutrient capsule containing 18 vitamins and minerals (including 20 mg iron) (hereafter, 117 
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MMN supplement or group); and (c) SQ-LNS with similar micronutrients as the MMN 118 
supplement, plus other minerals and macronutrients (hereafter, LNS supplement or group). 119 
Group allocations were developed by the Study Statistician at UC Davis using a computer-120 
generated (SAS version 9.3) randomization scheme (in blocks of nine), and were placed in 121 
sealed, opaque envelopes. At each enrolment, a Study Nurse offered nine envelopes at a time, 122 
and the woman picked one to reveal the allocation. Allocation information was kept securely by 123 
the Field Supervisor and the Study Statistician only.  124 
 The compositions of the 3 supplements were reported previously (Adu-Afarwuah et al., 125 
2015), as well as the  considerations underlying the concentrations of the nutrients in the MMN 126 
and SQ-LNS (Arimond et al., 2013). Apart from iron which was kept at 20 mg/day in the MMN 127 
and SQ-LNS, the vitamin and mineral contents were either 1x or 2x the RDA for pregnancy, or 128 
in a few cases, the maximum amount that could be included in the supplement given technical 129 
and organoleptic constraints. The IFA and MMN supplements were provided as capsules in 130 
blister packs, and were intended to be consumed with water after a meal, one capsule per day 131 
throughout pregnancy. The LNS supplement was in 20-g sachets, and was intended to be mixed 132 
with any prepared food, one sachet per day throughout pregnancy. To maintain blinding, two 133 
individuals independent of the study placed color-coded stickers behind the blister packs (three 134 
different colors for IFA and three for MMN supplements) so that the capsules were known to the 135 
study team and participants only by the colors of the stickers. Laboratory staff and data analysts 136 
had no knowledge of group assignment until all preliminary analyses had been completed and 137 
the allocation codes were broken. The study was registered on ClinicalTrials.gov (Identifier: 138 
NCT00970866) and was approved by ethics committees of the University of California, Davis, 139 
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We collected socio-demographic information at baseline, and determined GA mostly by 144 
ultrasound biometry (Aloka SSD 500, Tokyo, Japan). During follow-up, field workers visited 145 
women in their homes every two weeks, whereupon they delivered a fresh supply of supplement 146 
and monitored supplement intakes. At each of laboratory assessments at baseline and at 36 GW, 147 
women’s weight (Seca 874) and height (Seca 217) were measured, and peripheral malaria 148 
parasitemia (Clearview Malarial Combo, Vision Biotech, South Africa), hemoglobin, Hb 149 
(HemoCue AG, Wetzikon, Switzerland) and zinc protoporphyrin, ZPP (hematofluorometer, Aviv 150 
Biomedical Co. NJ, USA), were determined using venous blood (Adu-Afarwuah et al., 2015). 151 
We used the original Aviv cover-slides and 3-level control material for the ZPP measurements, 152 
after red blood cells were washed three times with normal saline. Plasma samples obtained after 153 
blood was centrifuged at 1,252 x g for 15 min were stored in Ghana at -20 ºC, before being air-154 
freighted on dry ice to UC Davis, where soluble transferrin receptor (TfR, mg/L), C-reactive 155 
protein (CRP, mg/L), and alpha-1 glycoprotein (AGP, g/L) concentrations were determined 156 
using a Cobas Integra 400 plus Automatic Analyzer (Roche Diagnostic Corp., Indianapolis, IN).   157 
At 36 GW, the continuous outcomes measures were Hb (g/L), ZPP (µmol/mol heme), 158 
and plasma TfR (mg/L), CRP (mg/L), and AGP (g/L) concentrations, whilst the binary outcome 159 
measures were the percentages of women with low Hb, high Hb, and elevated ZPP, TfR, CRP 160 
and AGP.   161 
 162 
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Sample size and data analysis 163 
 For the Ghana iLiNS-DYAD Study, an effect size (Cohen’s d: difference between group 164 
means divided by the pooled standard deviation) of 0.3 (considered a small-to-moderate effect 165 
size) (Cohen) was the basis for sample size calculation. Thus, our sample size was based on 166 
detecting an effect size of 0.3 between any two groups for any continuous variable at 36 GW, 167 
with a two-sided 5% test and 80% power. As described previously (Adu-Afarwuah et al., 2015), 168 
we enrolled 1320 pregnant women into the study, but after excluding 177 who received both IFA 169 
and MMN supplements during pregnancy because of a temporary mislabeling of supplements, as 170 
well as 86 in the LNS group who were pregnant during the same time period, 1,057 women were 171 
included in the current analysis. Based on a sample size of 827 women (~275 per group) for 172 
whom data were available at 36 GW, we had 94% power to detect an effect size of 0.3 between 173 
any two groups for hemoglobin, ZPP, or TfR. This would allow a difference of 3.4 g/L in Hb, 8.9 174 
µmol/mol heme in ZPP, and 0.5 mg/L in TfR (given SD of 11.0, 30.0, and 2.0, respectively) to 175 
be detected between any 2 groups.   176 
 We posted the statistical analysis plan (www.ilins.org) before analysis. Statistical 177 
analysis, by intention-to-treat, was performed using SAS for Windows Release 9.3 (Cary, NC, 178 
USA). Background socio-demographic characteristics were summarized as mean ± SD for 179 
continuous variables, or number of participants and percentages for categorical variables. As 180 
done previously (Adu-Afarwuah et al., 2015), we used 2 indices, namely assets index and 181 
housing index as proxy indictors for socioeconomic status, and calculated household food 182 
insecurity access (HFIA) score (Coates et al., 2007) as a measure of degree of household food 183 
insecurity. Higher values of the assets and housing indices represented higher socioeconomic 184 
status, and higher values of the food insecurity index represented higher food insecurity.  185 
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We calculated adherence to treatment as percentage of days from enrolment to the home 186 
visit closest to the laboratory assessment at 36 GW, when women reported consuming the 187 
supplement. We used Hb <100 g/L as our primary definition for low Hb (representing anemia). 188 
This was based on previous WHO (WHO, 2007, WHO/UNICEF/UNU, 2001) and International 189 
Nutritional Anemia Consultative Group, INACG (Nestel and INACG Steering Committee, 2002) 190 
documents that suggest lowering the standard 110 g/L cut-off by 10 g/L for pregnant women of 191 
African extraction to achieve adequate sensitivity and specificity for screening purposes 192 
(WHO/UNICEF/UNU, 2001). In addition, we defined low Hb using the standard cut-off of Hb 193 
<110 g/L, based on  a recent WHO recommendation (WHO, 2011) to maintain that cut-off (110 194 
g/L) without any adjustment, because of scarce evidence to support the adjustment. A meta-195 
analysis (Haider et al., 2013) revealed that Hb cut-offs ranging from <100 g/L to 115 g/L have 196 
been used in studies to define anemia in pregnant women. We defined high Hb as >130 g/L 197 
(Pena-Rosas et al., 2012), elevated ZPP (proxy for iron deficiency) as >60 ȝmol/mol heme 198 
(Walsh et al., 2011) and elevated TfR (proxy for tissue iron deficiency) as > 6.0 mg/L (Pfeiffer et 199 
al., 2007, Vandevijvere et al., 2013). Because there is no generally accepted cut-off value for 200 
TfR, we derived the 6.0 mg/L cut-off based on the evidence that TfR values obtained using the 201 
Automatic Analyzer assay (as used in this study) were on average 30% lower than values 202 
obtained with the ELISA assay (Pfeiffer et al., 2007). Therefore, we reduced by 30% the 8.5 203 
mg/L cut-off value used when TfR was determined using ELISA (Vandevijvere et al., 2013) to 204 
obtain the cut-off of approximately 6.0 mg/L for our analysis. Because we used 2 cut-offs to 205 
define anemia, we also defined iron deficiency anemia (IDA) in two ways:  first as Hb <100 g/L 206 
and at least one marker of iron deficiency (ZPP > 60 (µmol/mol heme) or TfR >6.0 mg/L 207 
(Pfeiffer et al., 2007, Vandevijvere et al., 2013)), and second, as Hb <110 g/L and at least one 208 
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marker of iron deficiency. We defined elevated inflammatory markers using the cut-off values of 209 
>5.0 mg/L for CRP and  >1.0 g/L for AGP (Thurnham and McCabe), and categorized women 210 
with inflammation as either elevated CRP only (indicative of incubation phase of infection), 211 
elevated CRP and AGP (indicative of early convalescence) or elevated AGP only (indicative of 212 
late convalescence) (Thurnham and McCabe).  213 
At 36 GW, we calculated overall mean (±SD) values and percentages for Hb and markers 214 
of iron status and inflammation. We compared groups by using general linear models 215 
(continuous outcomes) and logistic regression models (binary), with Tukey-Kramer adjustment 216 
for multiple comparisons. Along with the group comparisons, we calculated pairwise mean 217 
differences (continuous outcomes, ANOVA) and relative risks (binary outcomes, Logistic 218 
regression) with their 95% CI and p-values. Relative risks were calculated using Poisson 219 
regression (Spiegelman and Hertzmark, 2005). In addition, we analyzed changes in the 220 
prevalence of anemia, high Hb, and elevated ZPP, TfR, CRP and AGP from enrolment using 221 
mixed model logistic regression (SAS PROC GLIMMIX). Where the mixed model logistic 222 
regression failed to converge because of sparse data, we used generalized estimating equations 223 
model (SAS PROC GENMOD). We analyzed each outcome twice, first without any covariate 224 
adjustments, and then with adjustment for covariates significantly associated (p<0.10) with the 225 
outcome in a bivariate analysis. Because ZPP, TfR, AGP and CRP are not normally distributed, 226 
we calculated the group means (± SD or SE), group percentages, and pair-wise mean differences 227 
and relative risks with their 95% CI based on untransformed data, but generated the p-values for 228 
group or pair-wise comparisons using logarithmically transformed data.  229 
To investigate the possible effect of group differences in adherence to treatment, we 230 
performed a per-protocol analysis, which was restricted to women with adherence  70%. We 231 
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evaluated potential interaction of treatment group with pre-specified baseline variables for 232 
maternal characteristics, anemia and iron status. These variables were: age, years of schooling, 233 
BMI, gestational age at enrolment, household assets index, housing index, food insecurity access 234 
score, season at enrolment (dry or wet), primiparous, anemia, and elevated ZPP, TfR, and AGP 235 
or CRP. Where an interaction was significant (alpha <0.10), we performed subgroup analysis by 236 
including an interaction term between treatment and the effect modifier in the ANCOVA or 237 
logistic regression model. For continuous effect modifiers, we used data from all participants to 238 
create a linear regression model to predict the values of the outcome at the 10th and 90th 239 
percentile of the effect modifier distribution. Each effect modifier was considered separately in 240 
the models to avoid collinearity.  241 
In a sensitivity analysis aimed at correcting for the effect of inflammation (CRP and 242 
AGP) on the Hb and iron status outcomes, we repeated the above analyses using values of Hb 243 
and iron status markers corrected for inflammation (WHO, 2007). These corrected values were 244 
calculated by grouping women into 3 inflammation categories, estimating the correction factor 245 
(CF) for each inflammation category, and  multiplying the Hb and iron status values of each 246 
woman by the inflammation category-specific CF (Grant et al., 2012). The 3 inflammation 247 
categories were: reference (normal CRP and AGP), incubation (raised CRP and normal AGP), 248 
and early (raised CRP and AGP) or late (normal CRP and raised AGP) convalescence [these two 249 
phases of convalescence were combined because of small sample sizes and little indication of 250 
differences]. For ZPP at 36 GW, women were grouped into 2 inflammation categories (normal 251 
versus any inflammation), since the 3-category grouping did not yield consistent results. 252 
  253 
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Results    254 
We collected data from December 2009 to August 2012. The study flow diagram, as well 255 
as the main reasons women were not eligible, or were eligible but not enrolled, were reported 256 
elsewhere (Adu-Afarwuah et al., 2015). Among eligible women, those enrolled (n=1320) and 257 
those not enrolled (n=606) did not differ in most background characteristics (results not shown). 258 
The background characteristics of the 1057 women included in the current analysis are presented 259 
in Table 1. These characteristics were well-balanced across the three groups. On average, 260 
women were about 26 years of age, had about 7 years of formal education, and BMI of about 25 261 
kg/m3. Nearly all of the women said they were married or living with a partner, slightly more 262 
than a third were primiparous, and nearly 10% tested positive for malaria. The average GA at 263 
enrolment was 16 weeks. At baseline, we obtained Hb values for all 1057 women, ZPP values 264 
for 1055 women, and TfR, CRP and AGP values for 1032 women.   265 
At 36 GW, dropout (4.4%) was low, and did not differ among groups (p = 0.65). Women 266 
who dropped out – mainly because of miscarriage (2.8%) and movement from the study site 267 
(1.2%) –did not differ in the baseline characteristics from those who were present at 36 GW, 268 
except for GA (weeks) at enrolment, which was significantly lower (p = 0.001) for the former 269 
(14.5) than for the latter (16.3). Mean (±SD) adherence (% of days from enrolment to the home 270 
visit closest to the laboratory assessment at 36 GW when supplement was reportedly consumed) 271 
was lower (p=0.001) in the LNS group (68 ± 24) compared to the IFA (74 ± 21) and the MMN 272 
(72 ±23) groups. Women usually reported mixing the LNS supplement with porridge, but 273 
sometimes mixed it with other foods including soups and stews, or consumed it alone. We 274 
obtained Hb values for 827 women, and ZPP, TfR, CRP and AGP values for 822 women; the 275 
number (%) of women without Hb values did not differ between groups (p = 0.10). The women 276 
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with Hb values did not differ from those without Hb values in most of the baseline 277 
characteristics, except that the latter had lower mean housing index (-0.17 ± 1.09 vs. 0.04 ± 0.99; 278 
p = 0.011), BMI (24 ± 4.0 vs. 25 ± 4.7 kg/m2; p = 0.022) and GA at enrolment (16 ± 3.1 vs. 16 ± 279 
3.3 weeks; p = 0.042).  280 
In the intention-to-treat analysis, the overall mean (±SD) values at baseline and 36 GW 281 
were 112± 12 and 117 ± 12, respectively, for Hb (g/L), 45 ± 32 and 47 ± 30 for ZPP (ȝmol/mol 282 
heme) and 4.1 ± 2.5 and 4.5 ± 1.7 for TfR (mg/L). From baseline to 36 GW, the prevalence of 283 
anemia decreased significantly from 13% to 5.3% (p < 0.001), whilst the reverse was true for the 284 
prevalence of high Hb (4.9% vs 12%, p < 0.001) and elevated TfR (9.2%  to 15%; p = 0.001), 285 
with a moderate change in the prevalence of elevated ZPP (13% vs. 16%; p = 0.06). The mean 286 
(±SD) CRP (mg/L) and AGP (g/L) at baseline (6.9 ± 11 and 0.6 ± 0.2, respectively) were slightly 287 
greater than at 36 GW (5.7 ± 17 and 0.5 ± 0.2, respectively), which was also reflected in the 288 
percentages of women with elevated CRP and AGP at baseline vs. 36 GW (38.2% vs 24.1%; p < 289 
0.001 and 6.3% vs 2.8%; p < 0.001, respectively).   290 
 291 
Main group comparisons at 36 gestational weeks 292 
Table 2 shows the unadjusted mean (± SD) Hb (g/L), ZPP (ȝmol/mol heme), TfR (mg/L), 293 
CRP (mg/L) and AGP (g/L) concentrations, by intervention group, at baseline and 36 GW in the 294 
intention-to-treat analysis. Baseline values did not differ significantly among groups. At 36 GW, 295 
mean Hb was significantly (p < 0.001) greater in the IFA group (120 ±11) than in the LNS 296 
(115±12) or MMN (117±12) group; ZPP was significantly (p <0.001) lower in the IFA group (43 297 
± 30) than in the LNS (50± 29) or MMN (49 ± 30) group; and TfR was significantly (p < 0.001) 298 
lower in the IFA group (4.0 ± 1.3) than in the LNS (4.9±1.8) or MMN (4.6±1.7) group. Further 299 
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(Table 3), the percentage of women with anemia defined either as Hb <100 g/L or Hb <110 g/L 300 
was significantly lower in the IFA group compared with the LNS and MMN groups, and when 301 
using the latter definition, this percentage was also significantly greater in the LNS compared 302 
with the MMN group. Compared with the IFA group, the LNS and MMN groups had greater 303 
percentages of women with elevated ZPP (9.4% vs 19% and 19%, respectively; p = 0.003) and 304 
elevated TfR (9.0% vs 19% and 15 %, respectively; p = 0.004). Differences among the 3 groups 305 
in the prevalence of IDA were marginally significant (p = 0.07) when the Hb cut-off of 100 g/L 306 
was used in the definition of IDA, but were significant (p <0.001) when the Hb cut-off of 110 307 
g/L was used. In the latter situation, the risk of IDA was significantly greater in the LNS group 308 
compared with the IFA group (p < 0.001), and marginally greater in the MMN compared to the 309 
IFA group, and in the LNS compared with the MMN group. The prevalence of high Hb did not 310 
differ among groups (p = 0.15).  311 
From baseline to 36 GW, the decrease in the prevalence of anemia (based on our primary 312 
definition of Hb <100 g/L) and increase in the prevalence of high Hb were significant for all 313 
groups; the change in prevalence over time differed between groups for anemia (P-interaction = 314 
0.099) but not for high Hb (P-interaction = 0.95). For elevated ZPP, the increase in prevalence 315 
from baseline was marginally significant in the LNS group (p = 0.06) and non-significant in the 316 
other two groups, and the change in prevalence over time did not differ between groups (P-317 
interaction = 0.14). For elevated TfR, the increase in prevalence was significant for the LNS (p = 318 
0.003) and MMN (p = 0.009) groups only, and the change in prevalence over time did not differ 319 
between groups (P-interaction = 0.17). Apart from the prevalence of anemia defined using the 320 
Hb cut-off of 110 g/L, the LNS and MMN groups did not differ significantly in any of the 321 
continuous (Table 2) or binary (Table 3) Hb and iron status outcomes.  322 
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 There were no significant differences among groups in 36 GW mean (±SD) concentrations 323 
of CRP (p = 0.98) and AGP (p = 0.35) (Table 2), or the percentages of women in the incubation 324 
phase of infection (elevated CRP only; p = 0.26), early convalescence (both CRP and AGP 325 
elevated; p = 0.67) or late convalescence (elevated AGP only; p = 1.00). From baseline to 36 326 
GW, the decrease in the percentage of women in the incubation phase of infection was 327 
significant for all groups. For percentage of women in early convalescence, only the decrease in 328 
the IFA group (p = 0.010) was significant, and for percentage of women in late convalescence 329 
(where the mixed model logistic regression did not converge because of sparse data, and hence 330 
generalized estimating equations model was used), only the decrease in the MMN group (p = 331 
0.024) was significant. 332 
Adjustments by covariates significantly associated with Hb and the iron status (ZPP and 333 
TfR) and inflammatory (CRP and AGP) outcomes (including the baseline value for each 334 
outcome) did not alter the unadjusted results (data not shown). In addition, correcting the Hb and 335 
iron status values for inflammation in the sensitivity analysis (results not shown) did not change 336 
the above findings.      337 
The per-protocol analysis (results not shown) revealed that among women with adherence 338 
to treatment  70% (samples sizes at 36 gestational weeks: 213 in IFA, 222 in MMN and 166 in 339 
the LNS group, for Hb), the above findings remained unchanged, except for the fact that the 340 
prevalence of anemia (defined as Hb < 100 g/L or < 110 g/L) did not differ between the LNS and 341 
MMN groups, and the prevalence of IDA (if definition included Hb < 110 g/L) was greater only 342 
in the LNS compared with the IFA group.  343 
 344 
Effect modification 345 
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Interactions of treatment group with BMI, season of enrolment and elevated CRP 346 
concentration at baseline were not significant for any of the outcomes. As shown in Table 4, the 347 
effect of intervention on ZPP concentration at 36 GW was modified by baseline anemia (Hb < 348 
100 g/L; P-interaction = 0.099), elevated ZPP (P-interaction = 0.013) and TfR (P-interaction = 349 
0.090), GA at enrolment (P-interaction = 0.041), and household assets score (P-interaction = 350 
0.061).  Specifically, the difference in mean (±SD) ZPP concentration at 36 GW among 351 
intervention groups (MMN and LNS groups compared with the IFA group) was greater among  352 
women with anemia at baseline, elevated baseline ZPP, greater GA at enrolment, or lower 353 
household assets scores . Similarly, the difference in risk of elevated ZPP among intervention 354 
groups was greater in women with greater GA at enrolment (P-interaction = 0.057), and elevated 355 
TfR at baseline (P-interaction = 0.049)   356 
The difference in mean TfR concentration at 36 GW among intervention groups was 357 
greater among women who were anemic at baseline (P-interaction = 0.079), did not have 358 
elevated AGP at baseline (P-interaction = 0.051), or had greater GA at enrolment (P-interaction 359 
= 0.016), whereas the difference in risk of elevated TfR among intervention groups was greater 360 
in women with less food insecurity.   361 
For elevated CRP and AGP at 36 GW, there were significant interactions between 362 
intervention group and elevated ZPP at baseline (P-interaction = 0.008) and household assets 363 
score (P-interaction = 0.091), but the stratified analyses (Table 4) did not show consistent results.   364 
  365 
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Discussion 366 
 In the iLiNS-DYAD-Ghana study, pregnant women who were provided with standard 367 
iron (60 mg) and folic acid supplements from 20 GW had significantly greater mean Hb, lower 368 
mean ZPP and TfR and lower prevalence of anemia and iron deficiency (elevated ZPP and TfR) 369 
at 36 GW than pregnant women who were provided with either the MMN or LNS supplements, 370 
both of which contained 20 mg iron. Overall, however, the prevalence of anemia (Hb < 100 g/L) 371 
at 36 GW was relatively low (2.2-7.9%), and iron deficiency was evident in <20% of women in 372 
all groups. At 36 GW, the three groups did not differ in the percentage of women with high Hb 373 
(12.3% overall) or inflammation (CRP and AGP). These findings remained unchanged when 374 
analyses were restricted to women who were more adherent to treatment. 375 
A few weaknesses of our study were described previously (Adu-Afarwuah et al., 2015), 376 
namely: (a) a fully double-blind study design was not possible because of the physical 377 
differences between the SQ-LNS in the form of sachets, and the other two supplements (MMN 378 
and IFA) in the form of capsules, and (b) adherence to treatment was assessed by self-report and 379 
not direct observation. However, none of the individuals involved in sample collection, 380 
laboratory measurements or data analysis had any knowledge of group assignment. The good 381 
collaboration with the antenatal clinics (which gave women the confidence to cooperate), 382 
relatively low rate of attrition, intense follow-up of participants, and detailed attention we paid to 383 
ensuring data quality were notable strengths of the study. 384 
Several possible explanations may be relevant for the observed lower Hb and higher ZPP 385 
and TfR values in the MMN and LNS groups compared to the IFA group. First, the 20 mg iron 386 
dose used in the MMN and LNS supplements may have been too low for this Ghanaian 387 
population of pregnant women. In most (but not all) similar studies, the iron dose of the iron + 388 
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folic acid supplement was 60 mg/day and that of the multiple micronutrient supplement was 30 389 
mg/day (Allen and Peerson, 2009, Roberfroid et al., 2011, Mei et al., 2014), although in 390 
Indonesia (Suprapto et al., 2002), Mexico (Ramakrishnan et al., 2004), Nepal (Christian et al., 391 
2003) and Tanzania (Makola et al., 2003), both the iron + folic acid and multiple micronutrient 392 
supplement groups received iron doses of at least 50 mg/ day. In these studies (even for those 393 
that used multiple micronutrients containing 30 mg Fe), pregnant women consuming the multiple 394 
micronutrient supplements generally did not differ in Hb or iron status indicators compared to 395 
those consuming iron + folic acid (Allen and Peerson, 2009, Mei et al., 2014, Roberfroid et al., 396 
2011). A study of Australian women (Zhou et al., 2009) suggested that 20 mg iron per day may 397 
be an adequate dose to prevent iron deficiency anemia during pregnancy compared with higher 398 
doses of iron. However, the diet of the women in our sample, as is typical of Ghana, is mainly 399 
plant-based and high in phytate (Gibson, 1994), which reduces iron absorption (Baech et al., 400 
2003), so dietary iron needs during pregnancy may be higher in Ghana than in Australia.  401 
Another possibility is that the relatively high dose of zinc (30 mg) in the MMN and LNS 402 
supplements may have interfered with iron absorption, as suggested by the results of a 403 
supplementation trial in Nepal (Christian et al., 2003).  The lack of a good biomarker of zinc 404 
status at the individual level makes it difficult to explore this potential mechanism for the 405 
differences in iron status between the IFA and other two groups. 406 
It is noteworthy that there were no significant differences in mean Hb or iron status 407 
between the LNS and MMN groups, despite the fact that SQ-LNS is a food-based supplement 408 
rather than a capsule and some differences in composition could have affected these outcomes. 409 
For instance, it is possible that the calcium or phytate in SQ-LNS could have limited the 410 
absorption of iron in the LNS group. The lack of differences in Hb and iron status between these 411 
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two groups suggests that the iron or other micronutrient content (which was identical in these 412 
two supplements, except for the macro-minerals) was the most critical factor. 413 
In Ghana, anemia (Ghana Statistical Service (GSS) et al., 2009) and infections including 414 
malaria (Yatich et al., 2009) are common among pregnant women even in relatively high income 415 
communities, and evidence (Mockenhaupt et al., 2000) suggests that malaria is a major risk 416 
factor for anemia. Thus, it is noteworthy that the prevalence of both anemia and elevated CRP 417 
declined significantly in all three groups between baseline and 36 weeks gestation.    418 
It is important to consider the implications of the observed lower mean Hb of the SQ-LNS 419 
and MMN groups compared to the IFA group at 36 weeks gestation. Low Hb concentration or 420 
anemia in the first or second trimester of pregnancy is linked with poor pregnancy outcomes 421 
including low birth weight (Murphy et al., 1986), but no such association has been established 422 
for low Hb concentration or anemia in the third trimester (Allen, 2000). Further, Hb 423 
concentrations substantially above 110–119 g/L during pregnancy may be independent of iron 424 
status and have been linked  with poorer health outcomes for the mother and fetus (Yip, 2000, 425 
Zhou et al., 1998). Therefore, the higher mean Hb concentrations observed for women in the IFA 426 
group compared to those in the LNS and MMN groups in the third trimester (36 GW) may not 427 
necessarily be beneficial with respect to birth outcomes. In fact, we previously demonstrated that 428 
in this same study (Adu-Afarwuah et al., 2015) the prenatal consumption of LNS (compared to 429 
IFA) was associated with greater birth weight, weight-for-age z-score and BMI-for-age z-score, 430 
and that, in first-time mothers, prenatal LNS supplementation also increased birth length and 431 
head circumference and reduced the proportion of infants with low birth weight, low birth length, 432 
and small-for-gestational age. In this cohort, there was no relationship between Hb at 36 wk 433 
gestation and infant birth size, and there was actually a significant negative relationship between 434 
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maternal iron status at 36 wk and birth size (Oaks et al., 2015). Thus, the difference between the 435 
LNS and IFA groups in mean maternal Hb, ZPP, and TfR concentrations needs to be weighed 436 
against the difference (in the opposite direction) in birth outcomes. In two sets of analyses (Garn 437 
et al., 1981, Steer et al., 1995) each involving a large number of pregnant women, the lowest risk 438 
of adverse birth outcomes including low birth weight was seen in women with Hb ~95-105 g/L 439 
(Steer et al., 1995) or Hb ~100 -110 g/L (Garn et al., 1981). Appropriate cut-offs for ZPP and 440 
TfR in pregnancy are not well documented, particularly with respect to functional outcomes. 441 
Therefore, it is difficult to judge whether our results should be interpreted as “improvements” in 442 
maternal iron status in the IFA group compared to the MMN or LNS group.  443 
We conclude that among pregnant women in a semi-urban setting in Ghana,  444 
supplementation with SQ-LNS or MMN containing 20 mg iron resulted in lower Hb and iron 445 
status but had no impact on inflammation, when compared with iron (60 mg) plus folic acid (400 446 
µg) treatment. The amount of iron in such supplements that is most effective for improving both 447 
maternal Hb/iron status and birth outcomes requires further evaluation.  448 
 449 
Key messages 450 
1. In this semi-urban Ghanaian population, the prevalence of anemia (Hb <100 g/L) among 451 
pregnant women who received IFA, MMN or SQ-LNS was reduced from 13% at <20 452 
gestational weeks (GW) to 5% at 36 GW. 453 
2. Provision of IFA (with 60 mg Fe) was associated with a greater mean concentration of 454 
Hb and lower prevalence of anemia at 36 GW than provision of MMN or SQ-LNS (both 455 
with 20 mg Fe). 456 
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3. The prevalence of high Hb (>130 g/L) or elevated inflammatory biomarkers (CRP and 457 
AGP) at 36 GW was not affected by the type of prenatal supplement provided. 458 
4. More research is needed to determine the concentration of iron in MMN and SQ-LNS 459 
supplements that is most effective for improving both maternal Hb/iron status and birth 460 
outcomes.  461 
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TABLE 1 
Background characteristics of pregnant Ghanaian women whose hemoglobin, and iron status and inflammatory 
markers were analyzed at 36 gestational weeks, by intervention group1 
Background characteristics 
IFA  
(N = 349) 
MMN  
(N = 354) 
LNS  
(N = 354) 
Age, y 27 ± 5.3 [349] 27 ± 5.7 [354] 27 ± 5.4 [354] 
Formal education, y  7.6 ± 3.5 [349] 7.5 ± 3.6 [354] 7.7 ± 3.7 [354] 
Body Mass Index, kg/m2 25 ± 4.3 [342] 25 ± 5.0 [348] 25 ± 4.4 [349] 
Low BMI, n/N (%) 11/342 (3.2) 8/348 (2.3) 6/349 (1.7) 
Gestational age at enrolment, weeks 16.3 ± 3.3 [346] 16.2 ± 3.2 [353] 16.2 ± 3.3 [349] 
Assets index2 0.09 ± 0.98 [342] 0.1 ±  0.9 [349] -.01 ± 0.91 [348] 
Housing index2 0.04 ± 0.99 [342] -0.03 ± 1.03 [349] 0.00 ± 1.00 [348] 
HFIA Score3 2.9 ±  4.6 [345] 2.5 ±  3.9 [346] 2.5 ±  3.9 [348] 
Married or co-habiting, n/N (%) 320/349 (91.7) 332/354 (93.8) 328/354 (92.7) 
Primiparous women, n/N (%) 131/349 (37.5) 110/354 (31.1) 128/354 (36.2) 
Tested positive for malaria4, n/N (%) 31/349 (8.9) 30/354 (8.5) 40/354 (11.3) 
 
1 IFA= Iron-Folic Acid group; MMN=Multiple Micronutrients group. LNS= Small Quantity Lipid-based Nutrient 
Supplement group. HFIA is Household Food Insecurity Access Score.  N=total number of participants in the group 
in question; n = number of participants positive on the variable in question; % = percent of participants positive on 
the variable in question. Values are Mean ± SD [N] or n/N (%). 
2 Proxy indicators for household socioeconomic status; higher values represent higher socioeconomic status.  
3 HFIA (Household food insecurity access) is a proxy indicator for household food insecurity (Coates et al., 2007); 
higher values represent higher food insecurity 
4 Rapid Diagnostic Test (Clearview Malarial Combo, Vision Biotech, South Africa), which detected P. falciparum 
and non-P. falciparum histidine-rich protein-2 
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TABLE 2  
Unadjusted hemoglobin, and iron status and inflammatory markers of pregnant Ghanaian women at baseline and 36 gestational weeks, by intervention group, and 









P3 Comparison of IFA and 
MMN  
Comparison of IFA and 
LNS 
Comparison of MMN and 
LNS 
Mean difference (95 
% CI) 
p Mean difference  
(95 % CI) 
p Mean difference  
(95 % CI) 
p 
Hb, g/L           
     Baseline 
112 ± 13 
[349] 
111 ± 12 
[354] 
112 ± 12 
[354] 
 -1 (-4, 1)  0 (-2, 2)  1 (-1, 3)  
     36 GW 
120 ± 11 
[270] 
117 ± 12 
[291] 
115 ± 12 
[266] 
<0.001 -3 (-6, -1) 0.002 -5 (-7, 3) <0.001 -2 (-4, 1) 0.18 
ZPP, µmol/mol 
heme          
 
     Baseline 
43 ± 28 
[347] 
46 ± 36 
[354] 
45 ± 33 
[354] 
 3 (-3, 8)  2 (-4, 8)  -1 (-6, 5)  
     36 GW 42 ± 30 [267] 
49 ± 30 
[291] 
50 ± 29 
[264] 
<0.001 6 (0, 12) <0.001 7 (1, 13) <0.001 1 (-5, 7) 0.91 
TfR, mg/L           
     Baseline 
4.0 ± 1.9 
[338] 
4.0 ± 1.7 
[348] 
4.3 ± 3.5 
[346] 
 0.0 (-0.4,  0.5)  0.3 (-0.1,  0.8)  0.3 (-0.1,  0.8)  
     36 GW 4.0 ± 1.3 [266] 
4.6 ± 1.7 
[291] 
4.9 ± 1.8 
[265] 
<0.001 0.5 ( 0.2,  0.9) <0.001 0.8 ( 0.5,  1.2) <0.001 0.3 (-0.0,  0.6) 0.07 
CRP, mg/L           
     Baseline 7.9 ± 14  [338] 
5.8 ± 8.3  
[348] 
6.9 ± 11  
[346] 
 -2.1 (-4.1, -0.1)  -1.1 (-3.1,  1.0)  1.0 (-1.0,  3.0)  
     36 GW 5.6 ± 18  [266] 
5.7 ± 14  
[291] 
5.9 ± 18  
[265] 
0.85 0.1 (-3.3,  3.5) 0.95 0.3 (-3.2,  3.8) 0.97 0.2 (-3.2,  3.6) 0.84 
AGP, g/L           
     Baseline 
0.7 ± 0.2  
[338] 
0.6 ± 0.2  
[348] 
0.6 ± 0.2  
[346] 
 0.0 (-0.1,  0.0)  0.0 (-0.1,  0.0)  0.0 (0.0,  0.0)  
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     36 GW 
0.5 ± 0.2 
 [266] 
0.5 ± 0.2  
[291] 
0.5 ± 0.2  
[265] 
0.30 0.0 (0.0,  0.1) 0.65 0.0 (0.0,  0.0) 0.80 0.0 (-0.1,  0.0) 0.27 
 
 
1IFA= Iron-Folic Acid group; MMN=Multiple Micronutrients group; LNS= Small Quantity Lipid-based Nutrient Supplement group. AGP, CRP, GW, Hb, TfR, 
and ZPP are alpha-1 acid glycoprotein, C-reactive protein, gestational weeks, hemoglobin, transferrin receptor, and zinc protoporphyrin, respectively. Analyses 
are based on ANOVA (SAS, PROC GLM). Group means (±SD) and pair-wise mean difference (95% CI) were calculated using untransformed data. Except for 
Hb, all p-values for group or pair-wise comparisons were generated from log-transformed data; untransformed data were used for comparisons of mean Hb 
values. N=total number of participants in the group in question. 
2 Values are Mean ± SD [N]. 
3P-values, with Tukey-Kramer adjustments, compare all three groups. 
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TABLE 3   
Number (percentage) of pregnant Ghanaian women with abnormal hemoglobin, and iron status and inflammatory markers at baseline and 36 weeks of gestation, 







P3 Comparison of 
IFA and MMN4 
Comparison of 
IFA and LNS4 
Comparison of 
MMN and LNS4 
RR (95 % CI) p 
 
RR (95 % CI) p 
 
RR (95 % CI) p 
 
Low Hb (< 100 g/L)5           
     Baseline 39/349 (11.2) 51/354 (14.4) 47/354 (13.3)  1.29 (0.81, 2.05)  1.19 (0.74, 1.91)  0.92 (0.59, 1.43)  
     36 GW 6/270 (2.2) 17/291 (5.8) 21/266 (7.9) 0.019 2.63 (0.88, 7.86) 0.09 3.55 (1.22, 10.3) 0.013 1.35 (0.65, 2.83) 0.60 
Low Hb (< 110 g/L)6           
     Baseline 139/349 (39.8) 157/354 (44.4) 134/354 (37.9)  1.11 (0.90, 1.37)  0.95 (0.76, 1.19)  0.85 (0.69, 1.06)  
     36 GW 38/270 (14.1) 69/291 (23.7) 88/266 (33.1) <0.001 1.68 (1.10, 2.59) 0.011 2.35 1.56, 3.53) <0.001 1.40 (1.01, 1.92) 0.038 
High Hb7           
     Baseline 21/349 (6.0) 15/354 (4.2) 16/354 (4.5)  0.70 (0.33, 1.52)  0.75 (0.35, 1.60)  1.07 (0.47, 2.43)  
     36 GW 42/270 (15.6) 32/291 (11.0) 28/266 (10.5) 0.15 0.71 (0.42, 1.18) 0.25 0.68 (0.40, 1.16) 0.20 0.96 (0.54, 1.70) 0.98 
Elevated ZPP8           
     Baseline 40/347 (11.5) 54/354 (15.3) 46/354 (13.0)  1.32 (0.84, 2.09)  1.13 (0.70, 1.81)  0.85 (0.55, 1.32)  
     36 GW 25/267 (9.4) 56/291 (19.2) 49/264 (18.6) 0.003 2.06 (1.21, 3.48) 0.003 1.98 (1.16, 3.40) 0.007 0.96 (0.64, 1.46) 0.98 
Elevated TfR9           
     Baseline 29/338 (8.6) 29/348 (8.3) 37/346 (10.7)  0.97 (0.54, 1.75)  1.25 (0.72, 2.17)  1.28 (0.74, 2.23)  
     36 GW 24/266 (9.0) 44/291 (15.1) 51/265 (19.2) 0.004 1.68 (0.96, 2.94) 0.08 2.13 (1.24, 3.67) 0.003 1.27 (0.82, 1.97) 0.40 
IDA10           
     Baseline 20/338 (5.9) 22/348 (6.3) 22/346 (6.4)  1.07 (0.53, 2.15)  1.07 (0.53, 2.17)  1.01 (0.51, 1.99)  
     36 GW 2/264 (0.8) 11/291 (3.8) 11/263 (4.2) 0.07 4.99 (0.83, 29.9) 0.09 5.52 (0.92, 33.1) 0.06 1.11 (0.42, 2.95) 0.97 
IDA11           
     Baseline 36/338 (10.7) 37/348 (10.6) 37/346 (10.7)  1.00 (0.59, 1.68)  1.00 (0.60, 1.69)  1.01 (0.60, 1.68)  
     36 GW 12/264 (4.5) 27/291 (9.3) 41/263 (15.6) <0.001 2.04 (0.93, 4.49) 0.08 3.43 (1.63, 7.20) <0.001 1.68 (0.97, 2.90) 0.07 
Elevated CRP only12           
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     Baseline 113/338 (33.4) 108/348 (31.0) 121/346 (35.0)  0.93 (0.72, 1.20)  1.05 (0.82, 1.34)  1.13 (0.87, 1.45)  
     36 GW 49/266 (18.4) 70/291 (24.1) 59/265 (22.3) 0.26 1.31 (0.89, 1.93) 0.24 1.21 (0.81, 1.81) 0.52 0.93 (0.64, 1.33) 0.87 
Elevated CRP+AGP13           
     Baseline 26/338 (7.7) 15/348 (4.3) 11/346 (3.2)  0.56 (0.27, 1.17)  0.41 (0.18, 0.94)  0.74 (0.30, 1.84)  
     36 GW 7/266 (2.6) 9/291 (3.1) 5/265 (1.9) 0.67 1.18 (0.37, 3.77) 0.94 0.72 (0.18, 2.79) 0.83 0.61 (0.17, 2.22) 0.64 
Elevated AGP only14           
     Baseline 3/338 (0.9) 5/348 (1.4) 5/346 (1.4)  1.62 (0.30, 8.88)  1.63 (0.30, 8.93)  1.01 (0.23, 4.38)  
     36 GW 1/266 (0.4) 0/291 (0.0) 1/265 (0.4) 1.00       
 
1IFA= Iron-Folic Acid group; MMN=Multiple Micronutrients group; LNS=Small Quantity Lipid-based Nutrient Supplement group. AGP, CRP, GW, Hb, IDA, 
TfR, and ZPP are alpha-1 acid glycoprotein, C-reactive protein, gestational weeks, hemoglobin, iron deficiency anemia, transferrin receptor, and zinc 
protoporphyrin, respectively. N=total number of participants in the group in question. 
2Values are number of participants positive on the variable in question/N (% of participants positive on the variable in question). 
3P-vaues compare all three groups, with Tukey-Kramer adjustment, using logistic regression (SAS PROC LOGISTIC). 
4Relative Risks, RR(95% CI) and their p-values are based on Poisson regression (Spiegelman and Hertzmark, 2005). 
5 Nestel and INACG Steering Committee, 2002, WHO, 2007, WHO/UNICEF/UNU, 2001. 
6 WHO, 2011. 
7Hb >130 g/L (Pena-Rosas et al., 2012). 
8ZPP > 60.0 (µmol/mol heme). 
9TfR >6.0 mg/L (Pfeiffer et al., 2007, Vandevijvere et al., 2013). 
10Hb <100 g/L (Nestel and INACG Steering Committee, 2002, WHO, 2007, WHO/UNICEF/UNU, 2001) and at least one marker of iron deficiency (ZPP > 60.0 
(µmol/mol heme) or TfR >6.0 mg/L (Pfeiffer et al., 2007, Vandevijvere et al., 2013)). 
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11Hb <110 g/L (WHO, 2011) and at least one marker of iron deficiency (ZPP > 60.0 (µmol/mol heme) or TfR >6.0 mg/L (Pfeiffer et al., 2007, Vandevijvere et 
al., 2013)). 
12CRP >5.0 mg/L and AGP not >1.0 g/L (Thurnham and McCabe). 
13 CRP >5.0 mg/L and AGP  >1.0 g/L (Thurnham and McCabe). 
14 CRP not  > 5.0 mg/L and AGP >1.0 g/L (Thurnham and McCabe).  
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TABLE 4 





LNS2 P3 P4 Comparison of MMN 
and IFA (n = 349) 
Comparison of LNS and 
IFA (n = 354) 
Comparison of LNS and 
MMN (n = 354) 
Difference or RR P Difference or RR P Difference or RR P 
ZPP, µmol/mol heme5            
        Baseline anemia    0.099   .  .  . 
            No† 44 ± 2 
[233] 
47 ± 2 
[245] 
48 ± 2  
[226] 
 0.09 3 (-2, 9) 0.34 5 (-0, 11) 0.08 2 (-4, 8) 0.71 
            Yes 36 ± 6 
[26] 
54 ± 5 
[41] 
53 ± 5 
[33] 
 0.013 18 (3, 34) 0.017 18 (1, 34) 0.032 -1 (-16, 14) 0.99 
            
     Elevated baseline ZPP    0.013   .  .  . 
            No  42 ± 2 
[230] 
46 ± 2 
[242] 
46 ± 2 
[226] 
 0.19 3 (-2, 9) 0.34 4 (-2, 10) 0.20 1 (-5, 7) 0.94 
            Yes 47 ± 5 
[29] 
64 ± 5 
[44] 
72 ± 5 
[33] 
 0.001 18 (3, 32) 0.015 25 (9, 41) 0.001 8 (-7, 22) 0.43 
            
     Elevated baseline TfR    0.090   .  .  . 
            No  43 ± 2 
[239] 
47 ± 2 
[261] 
49 ± 2 
[233] 
 0.06 4 (-2, 9) 0.28 6 (0, 12) 0.048 2 (-4, 8) 0.65 
            Yes 41 ± 6.5 
[20] 
63 ± 6 
[25] 
59 ± 6 
[26] 
 0.017 22 (3, 41) 0.017 18 (-1, 36) 0.07 -4 (-22, 14) 0.84 
            
      GA at enrolment      0.041   .  .  . 
            At 10th percentile‡ 46 ± 3 51 ± 3 44 ± 3  0.28 5 (-5, 15) 0.44 -1 (-11, 9) 0.97 -6 (-16, 4) 0.29 
            At 90th percentile 40 ± 3 48 ± 3 54 ± 3  0.002 7 (-1, 16) 0.12 13 (5, 22) 0.001 6 (-3, 15) 0.25 
            
        Assets score      0.061   .  .  . 
            At 10th percentile 40 ± 3 46 ± 3 54 ± 3  0.003 5 (-4, 15) 0.38 14 (4, 24) 0.002 8 (-1, 18) 0.11 
            At 90th percentile 46 ± 3 50 ± 3 46 ± 3  0.37 5 (-4, 13) 0.44 -0 (-9, 9) 1.00 -5 (-14, 4) 0.46 
            
Elevated ZPP6            
      GA at enrolment      0.057   .  .  . 






 0.06 3.0 (0.9, 4.6) 0.12 1.0 (0.4, 2.5) 1.00 0.5 (0.2, 1.1) 0.11 






 0.004 2.4 (1.0, 5.7) 0.049 3.4 (1.5, 7.7) 0.003 1.4 (0.8, 2.5) 0.46 






LNS2 P3 P4 Comparison of MMN 
and IFA (n = 349) 
Comparison of LNS and 
IFA (n = 354) 
Comparison of LNS and 
MMN (n = 354) 
Difference or RR P Difference or RR P Difference or RR P 
            
     Elevated baseline TfR    0.049   .  .  . 






 0.008 2.2 (1.2, 4.0) 0.006 1.8 (1.0, 3.4) 0.08 0.8 (0.5, 1.3) 0.61 






 0.014 1.3 (0.4, 4.6) 0.41 2.7 (0.8, 9.4) 0.016 2.1 (0.7, 6.1) 0.14 
            
TfR, mg/L7            
        Baseline anemia    0.079   .  .  . 
            No 4.1 ± 0.1 
[232] 
4.5 ± 0.1 
[245] 
4.8 ± 0.1 
[226] 
 <0.001 0.4 (0.1, 0.8) 0.004 0.7 (0.4, 1.0) <0.001 0.3 (-0.0, 0.6) 0.11 
            Yes 3.5 ± 0.3 
[26] 
4.8 ± 0.3 
[41] 
5.0 ± 0.3 
[33] 
 <0.001 1.3 (0.4, 2.1) 0.002 1.5 (0.6, 2.4) <0.001 0.2 (-0.6, 1.1) 0.76 
            
        Elevated baseline AGP    0.051   .  .  . 
            No  4.1 ± 0.1 
[238] 
4.6 ± 0.1 
[272] 
4.9 ± 0.1 
[250] 
 <0.001 0.6 (0.3, 0.9) <0.001 0.8 (0.5, 1.2) <0.001 0.3 (-0.02, 0.6) 0.07 
            Yes 4.0 ± 0.4 
[20] 
4.0 ± 0.4 
[14] 
3.3 ± 0.5 
[9] 
 0.503 -0.0 (-1.2, 1.2) 1.00 -0. 7 (-2.1, 0.8) 0.51 -0.66 (-2.2, 0.8) 0.56 
            
      GA at enrolment      0.016   .  .  . 
            At 10th percentile 4.4 ± 0.2 5.0 ± 0.2 4.8 ± 0.2  0.023 0.9 (0.1, 1.1) 0.019 0.4 (-0.1, 0.9) 0.16 -0.2 (-0.7, 0.3) 0.64 
            At 90th percentile 3.8 ± 0.1 4.3 ± 0.1 4.9 ± 0.1  <0.001 0.5 (0.0, 0.9) 0.041 1.1 (0.7, 1.6) <0.001 0.7 (0.2, 1.1) 0.002 
            
Elevated TfR8            
      HFIA score      0.047   .  .  . 






 0.004 2.3 (1.1, 4.7) 0.006 2.5 (1.2, 5.0) 0.007 1.1 (0.6, 1.8) 1.00 






 0.06 0.7 (0.2, 2.0) 0.50 1.9 (0.8, 4.6) 0.27 2.8 (0.9, 8.7) 0.06 
            
Elevated CRP9            
     Elevated baseline ZPP    0.008   .  .  . 






 0.013 1.6 (1.1, 2.4) 0.014 1.2 (0.8, 1.8) 0.71 0.7 (0.5, 1.1) 0.11 






 0.09 0.5 (0.2, 1.1) 0.17 1.1 (0.5, 2.1) 0.99 2.1 (0.9, 4.9) 0.10 






LNS2 P3 P4 Comparison of MMN 
and IFA (n = 349) 
Comparison of LNS and 
IFA (n = 354) 
Comparison of LNS and 
MMN (n = 354) 
Difference or RR P Difference or RR P Difference or RR P 
            
Elevated AGP10            
      Assets score      0.091   .  .  . 






 0.39 1.0 (0.1, 9.8) 1.00 2.8 (0.6, 14.1) 0.51 2.8 (0.3, 28.0) 0.48 






 0.14 1.0 (0.2, 4.5) 1.00 0.16 (0.0, 1.3) 0.16 0.2 (0.0, 1.4) 0.14 
 
1IFA= Iron-Folic Acid group; MMN=Multiple Micronutrients group; LNS=Small Quantity Lipid-based Nutrient Supplement group. GA, Hb, HFIA, TfR, and 
ZPP are gestation age, hemoglobin, household food insecurity access, transferrin receptor, and Zinc protoporphyrin, respectively. Baseline anemia is Hb <100 
g/L (Nestel and INACG Steering Committee, 2002, WHO, 2007, WHO/UNICEF/UNU, 2001). Analyses are based on ANCOVA (SAS PROC MIXED, with 
SLICE option) for continuous outcomes or logistic regression (SAS PROC GLIMMIX, with SLICE option) for binary outcomes. Linear regression modeling 
was used to predict the outcome at the 10th and 90th percentile of continuous baseline effect modifiers. 
2Values are mean ± SE [total number of participants], or mean ± SE, or percent of participants positive on the variable in question (95% CI) or number of 
participants positive on the variable in question/total number of participants (percent of participants positive on the variable in question). Values are adjusted 
for variables significantly associated with the outcome variable in bivariate analysis.  
3P-values are for interaction with the outcome in question 
4P-values compare all three groups in each stratum. 
5ZPP values are adjusted for age, parity, season at enrolment, and baseline Hb, ZPP, and TfR concentrations.  
6Elevated ZPP (ZPP >60 µmol/mol heme) adjusted for age, education, and baseline Hb, ZPP and TfR concentrations. 
7TfR values are adjusted for age, season at enrolment, and baseline Hb, ZPP, TfR and AGP concentrations. 
8Elevated TfR (TfR > 6.0 mg/L) adjusted for age, gestational age enrolment, season at enrolment, and baseline Hb, ZPP, and TfR concentrations. 
9Elevated CRP (CRP > 5.0 mg/L) adjusted for BMI, household food insecurity access score, and baseline ZPP, AGP and CRP concentrations. 
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10Elevated AGP (AGP > 1.0 g/L) adjusted for age, parity, and season as enrolment. 
†Values are group mean ± SE [number of participants], and difference in means (95% CI) and p-values. All such values. 
‡Values are group mean ± SE, and difference in means (95% CI) and p-values. All such values. 
§Values are group % (95% CI), and relative risk (95% CI) and p-values. All such values. 
¶Values are number of participant (%), and relative risk (95% CI) and p-values. All such values. 
 
 
 
 
 
 
 
